The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV

The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV

AIMS: This prespecified exploratory analyses from VERTIS CV (NCT01986881) aimed to assess the effects of the sodium-glucose cotransporter-2 (SGLT2) inhibitor ertugliflozin on glucosuria-related (glycated haemoglobin [HbA1c], uric acid, body weight) and natriuresis-related (blood pressure, haemoglobi...

Full description

Bibliographic Details
Main Authors: Cannon, C.P (Author), Cherney, D.Z.I (Author), Cosentino, F. (Author), Dagogo-Jack, S. (Author), Frederich, R. (Author), Liu, C.-C (Author), Liu, J. (Author), Maldonado, M. (Author), Pong, A. (Author), Pratley, R.E (Author), VERTIS CV Investigators (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
adverse event
antidiabetic agent
biological marker
Biomarkers
body weight
Body Weight
Bridged Bicyclo Compounds, Heterocyclic
cardiovascular disease
chronic kidney failure
complication
controlled study
Diabetes Mellitus, Type 2
diabetic nephropathy
ertugliflozin
female
Female
fused heterocyclic rings
glucosuria
Glycated Hemoglobin A
Glycosuria
glycosylated hemoglobin
human
Humans
Hypoglycemic Agents
male
Male
natriuresis
Natriuresis
non insulin dependent diabetes mellitus
randomized controlled trial
randomized trial
Renal Insufficiency, Chronic
SGLT2 inhibitor
Sodium-Glucose Transporter 2 Inhibitors
type 2 diabetes
uric acid
Uric Acid
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items